elines for the elimination of MRSA transmission include
a risk assessment to identify high-risk areas for MRSA within the
hospital; surveillance program to outline activities and procedures
to identify MRSA cases; adherence to CDC hand hygiene guidelines;
use of contact precautions (e.g., gloves, gowns and separating MRSA
patients from other patients); environmental and equipment cleaning
and decontamination, especially items that are close to patients
such as bedrails and bedside equipment, and targeted active
surveillance cultures (testing of high-risk groups).
APIC's mission is to improve health and patient safety by
reducing risks of infection and other adverse outcomes. The
Association's more than 11,000 members have primary responsibility
for infection prevention, control and hospital epidemiology in
health care settings around the globe. APIC advances its mission
through education, research, collaboration, practice guidance,
public policy, and credentialing. Visit APIC online at http://www.apic.org
CONTACT: Jonathan Osmundsen, +1-202-261-2869, Cell:
+1-512-751-5309,, for APIC jonathan.osmundsen@mslpr.com
Web site: http://www.apic.org/
Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights
reserved.
A United Business Media Company
'"/>Page: 1 2 3 Related medicine technology :1.
Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix
Provides Excellent Protection Against Lesions Caused by Most Common
Cancer-Causing Virus Types2.
Actilyse (alteplase) Recommended by National Institute for Health
and Clinical Excellence for Treatment of Acute Ischaemic Stroke3.
Positive Results Prompt US National Cancer Institute to Make Glivec
Available to Patients in Post-Surgical GIST Study4.
Positive Results Prompt US National Cancer Institute to Make
Gleevec Available To Patients in Post-Surgical Gist Study5.
First-of-its-Kind National Report Reveals Estimated High Prevalence
and Heavy Cost of Type 2 Diabetes Complications in America6.
Research Results on FluMist Presented at National Association of
Pediatric Nurse Practitioners Conference7.
Protox Announces Publication in Journal of the National Cancer
Institute Supporting PRX302 as Treatment for Prostatic Diseases8.
Calando Pharmaceuticals Publishes the First Non-Human Primate Study
on Targeted, Systemic Delivery of siRNA in National Academy of
Sciences Journal9.
Advanced Magnetics Announces Presentation of Ferumoxytol Data at
the National Kidney Foundation 2007 Spring Clinical Meetings10.
Controlling the Spread of Healthcare Associated Methicillin Resistant Staphylococcus aureus Requires Active Surveillance11.
Nationwide MRSA Prevalence Study to Demonstrate Full Scope of
Superbug Threat Facing U.S. Healthcare Facilities and Patients